Truist Securities Reiterates Buy Rating on Axsome Therapeutics (AXSM)

Truist Securities analyst Joon Lee reiterated a Buy rating and $150.00 price target on Axsome Therapeutics (NASDAQ: AXSM).

The analyst commented: "Strong Auvelity uptake should continue with greater share of Rx by PCPs and upstream utilization. Planned addition of sales reps disclosed this AM is welcome news to sustain momentum. In hindsight prior mgmnt guidance of $1-3BN in sales for Auvelity in MDD look conservative. On pipeline front, we see favorable risk/reward into Ph3 ADVANCE-2 and ACCORD-2 readouts in ADA by YE24. AXSM is well on it's way to becoming a diversified biopharma in CNS with approval of 2nd product, AXS-07 for migraine, on the horizon. Reiterate BUY."

For an analyst ratings summary and ratings history on Axsome Therapeutics click here. For more ratings news on Axsome Therapeutics click here.

Shares of Axsome Therapeutics closed at $90.98 yesterday.

You May Also Be Interested In

• Ferguson Enterprises to Join S&P 500; ADI Global Distribution to Join S&P SmallCap 600
• Upexi receives Nasdaq minimum bid price deficiency notice
• Gamma Resources plans $880,000 private placement, cancels prior offering